Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|December 1, 2010
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rateSuzanne Svobodová, Judy Browning, Duncan MacGregor, et al.
Lab on a Chip|April 16, 2015
Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell trapsXi Qin, Sunyoung Park, Simon P Duffy, et al.
Future Oncology (London, England)|August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
Asia-Pacific Journal of Clinical Oncology|January 31, 2022
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysisGrace Chazan, Angelyn Anton, Shirley Wong, et al.
European Urology|November 5, 2019
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysisNiranjan J Sathianathen, Samantha Koschel, Isaac A Thangasamy, et al.
Diagnostics (Basel, Switzerland)|January 14, 2021
Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too LateMaarten J IJzerman, Jasper de Boer, Arun Azad, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 27, 2016
Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic RatchetsEmily S Park, Chao Jin, Quan Guo, et al.
BJU International|October 23, 2019
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)Michael S Hofman, Louise Emmett, John Violet, et al.
Future Oncology (London, England)|January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study designNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
Future Oncology (London, England)|January 17, 2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Joan Carles, et al.
Pageof 6